Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus topical - Palvella Therapeutics/TransDerm

X
Drug Profile

Sirolimus topical - Palvella Therapeutics/TransDerm

Alternative Names: PTX 022; QTORIN™ 3.9% rapamycin; QTORIN™ 3.9% rapamycin anhydrous gel; Rapamycin topical - Palvella Therapeutics/TransDerm; TD201

Latest Information Update: 30 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palvella Therapeutics; TransDerm
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pachyonychia congenita
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Lymphangioma; Pachyonychia congenita
  • Phase II Basal cell nevus syndrome

Most Recent Events

  • 22 Oct 2024 Palvella Therapeutics plans the phase II TOIVA trial in Vascular Malformations (In children, In adults, In the elderly, In Adolescents) (Topical, Gel), December 2024 (NCT06653842)
  • 01 Jul 2024 Phase-III clinical trials in Lymphangioma in USA (Topical) (NCT06239480)
  • 01 Dec 2023 Palvella Therapeutics has patent pending for anhydrous gel formulations of rapamycin in Europe, and Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top